Last reviewed · How we verify
Zirconium Cyclosilicate
Zirconium cyclosilicate is a non-absorbed potassium binder that traps potassium in the gastrointestinal tract and increases fecal potassium excretion.
Zirconium cyclosilicate is a non-absorbed potassium binder that traps potassium in the gastrointestinal tract and increases fecal potassium excretion. Used for Hyperkalemia in adults.
At a glance
| Generic name | Zirconium Cyclosilicate |
|---|---|
| Also known as | ZS |
| Sponsor | AstraZeneca |
| Drug class | Potassium binder |
| Target | Potassium ion (K+) in gastrointestinal tract |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The drug is a microporous, inorganic compound that selectively binds potassium ions in the colon through ion-exchange mechanisms. By binding potassium in the GI tract, it prevents reabsorption and increases elimination via feces, thereby reducing serum potassium levels without systemic absorption.
Approved indications
- Hyperkalemia in adults
Common side effects
- Constipation
- Nausea
- Abdominal discomfort
Key clinical trials
- An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia (PHASE3)
- A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients (PHASE3)
- Swedish Cardiac And Renal Failure Study-1 (PHASE2)
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (PHASE3)
- A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece
- Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study (PHASE4)
- Comparison of Potassium Binders in the ER (PHASE4)
- Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zirconium Cyclosilicate CI brief — competitive landscape report
- Zirconium Cyclosilicate updates RSS · CI watch RSS
- AstraZeneca portfolio CI